We also evaluated the association between change in sPD-L1 and survival, and observed that increase of sPD-L1 on therapy is related to worse survival outcome both in CheckMate 009/RCC and in CheckMate 038-P1/melanoma (figure 5, online supplemental figure S5C). Here, SPDL1 is linked to renal cell carcinoma.